Infectious Disease Virtual Conference

Presented by Maxim Group

May 5th 2020 10:00 am - 5:00 pm ET


Add to Calendar

One-On-One Meetings

Join a password protected virtual room for One-On-One meetings with each of our participating companies.

Conference Overview

The need for new anti-infectives (bacterial, fungal and viral) could never be greater — COVID-19 should be a warning of how quickly the world can be caught off guard. However, while COVID-19 has captured the world's attention for now, and rightfully so, there is another pandemic that has been smoldering beneath the surface; drug resistant bacteria and fungi driving alarming rates of invasive disease which result in high rates of mortality and a significant burden on the healthcare system. The lag in development of novel anti-infectives is multi-factorial, but as we move through 2020 and beyond, there is indeed a renaissance in drug development taking place that has not been observed for some time. This includes novel drugs and new drug classes, changes in regulatory guidelines and incentives for drug developers, changes to clinical trial design and execution, changes in views from payers and the investment community. Please join us as we hear from four panels of companies in various stages of development, from early stage to near commercialization, that represent the next wave of innovation in the infectious disease sector.


Keynote Speaker

10:00 am - 10:30 am

1st Panel: Non-antibiotic Anti-infectives

10:30 am - 12:00 pm

2nd Panel: Antifungals

12:15 pm - 1:45 pm

3rd Panel: COVID-19 (Vaccines and Monitoring)

2:15 pm - 3:30 pm

4th Panel: COVID-19 (Therapeutics)

3:45 pm - 5:00 pm

Keynote Speaker

Dr. Roger J. Pomerantz, M.D., F.A.C.P.,
President, CEO, and Chairman

ContraFect - CFRX


1st Panel

Non-antibiotic Anti-infectives


Aptorum Group - APM

Aridis Pharmaceuticals - ARDS

Armata  Pharmaceuticals - ARMP

ContraFect - CFRX

Daré Bioscience - DARE


2nd Panel



Amplyx Pharmaceuticals - PRIVATE

Appili Therapeutics - APLI

Cidara Therapeutics - CDTX

Matinas BioPharma - MTNB



3rd Panel

COVID-19 (Vaccines and Monitoring)


AIM Immunotech - AIM

Applied DNA Sciences - APDN

Daxor Corporation - DXR

Inovio Pharmaceuticals - INO

Vaxart Inc - VXRT


4th Panel

COVID-19 (Therapeutics)


Aridis Pharmaceuticals - ARDS

Bellerophon Therapuetics - BLPH

Cidara Therapeutics - CDTX

INmune Bio - INMB

Pluristem Therapuetics - PSTI

Download The free eBook